Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

Abstract Background Acute respiratory distress syndrome (ARDS) is a fatal complication of coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human mesenchymal stem cells (MSCs) as a potential treatment for ARDS. In this phase 1 clinical trial, we present the safety, feasibili...

Full description

Bibliographic Details
Main Authors: Seyed-Mohammad Reza Hashemian, Rasoul Aliannejad, Morteza Zarrabi, Masoud Soleimani, Massoud Vosough, Seyedeh-Esmat Hosseini, Hamed Hossieni, Saeid Heidari Keshel, Zeinab Naderpour, Ensiyeh Hajizadeh-Saffar, Elham Shajareh, Hamidreza Jamaati, Mina Soufi-Zomorrod, Naghmeh Khavandgar, Hediyeh Alemi, Aliasghar Karimi, Neda Pak, Negin Hossieni Rouzbahani, Masoumeh Nouri, Majid Sorouri, Ladan Kashani, Hoda Madani, Nasser Aghdami, Mohammad Vasei, Hossein Baharvand
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Stem Cell Research & Therapy
Subjects:
COVID-19
SARS-CoV-2
Pneumonia
Acute respiratory distress syndrome
Mesenchymal stromal cells
Cell therapy
Online Access:https://doi.org/10.1186/s13287-021-02165-4

Internet

https://doi.org/10.1186/s13287-021-02165-4

Similar Items